NCT06597591 Virtual Reality Training for Inhibitory Control in Neurocognitive Disorders
| NCT ID | NCT06597591 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Nice |
| Condition | Cognitive Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 48 participants |
| Start Date | 2024-11-18 |
| Primary Completion | 2027-05-18 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 48 participants in total. It began in 2024-11-18 with a primary completion date of 2027-05-18.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Executive function disorders, such as inhibitory control (IC) difficulties, are very common in older adults with neurocognitive disorders (NCD). Management of these disorders is possible using traditional tools and tools based on new technologies, such as serious games and virtual reality (VR). However, today, few immersive tools exist that are specifically focused on IC training. The present study aims to evaluate the acceptability of an immersive application focused on IC in 48 patients with neurocognitive disorders. Participants that will test either an immersive (VR-headset) or a non-immersive (tablet) version of the application for 4 weeks, twice a week, and fill-in acceptability related questionnaires before, during and after the end of the intervention.
Eligibility Criteria
Inclusion Criteria: 1. consulting the Nice hospital Memory Center 2. diagnosis of Mild Neurocognitve Disorder or slight major neurocognitive disorder (DSM V) 3. 60 years old or more 4. presence of deficits in inhibitory control as assessed by the Frontal Assessment Battery 5. fluent in French 6. able to understand the informed consent form and voluntarily consents to participate Exclusion Criteria: 1. presence of significant vision or motor problems which would impact ability to perform the task 2. significant self-reported motion sickness 3. vulnerable persons as defined in articles L1121-5 to 8 of the French Public Health Code
Contact & Investigator
Aurélie MOUTON, MD
PRINCIPAL INVESTIGATOR
Centre Hospitalier Universitaire de Nice
Frequently Asked Questions
Who can join the NCT06597591 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Cognitive Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06597591 currently recruiting?
Yes, NCT06597591 is actively recruiting participants. Contact the research team at lemaire.j@chu-nice.fr for enrollment information.
Where is the NCT06597591 trial being conducted?
This trial is being conducted at Nice, France.
Who is sponsoring the NCT06597591 clinical trial?
NCT06597591 is sponsored by Centre Hospitalier Universitaire de Nice. The principal investigator is Aurélie MOUTON, MD at Centre Hospitalier Universitaire de Nice. The trial plans to enroll 48 participants.